|
1
|
Richters A, Aben KKH and Kiemeney LALM:
The global burden of urinary bladder cancer: An update. World J
Urol. 38:1895–1904. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lenis AT, Lec PM, Chamie K and Mshs MD:
Bladder cancer: A review. JAMA. 324:1980–1991. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Patel VG, Oh WK and Galsky MD: Treatment
of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J
Clin. 70:404–423. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Seidl C: Targets for therapy of bladder
cancer. Semin Nucl Med. 50:162–170. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kobatake K, Ikeda KI, Nakata Y, Yamasaki
N, Ueda T, Kanai A, Sentani K, Sera Y, Hayashi T, Koizumi M, et al:
Kdm6a deficiency activates inflammatory pathways, promotes M2
macrophage polarization, and causes bladder cancer in cooperation
with p53 dysfunction. Clin Cancer Res. 26:2065–2079. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tao L, Mu X, Chen H, Jin D, Zhang R, Zhao
Y, Fan J, Cao M and Zhou Z: FTO modifies the m6A level of MALAT and
promotes bladder cancer progression. Clin Transl Med. 11:e3102021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou Z, Zhang Z, Chen H, Bao W, Kuang X,
Zhou P, Gao Z, Li D, Xie X, Yang C, et al: SBSN drives bladder
cancer metastasis via EGFR/SRC/STAT3 signalling. Br J Cancer.
127:211–222. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gil J and O'Loghlen A: PRC1 complex
diversity: Where is it taking us? Trends Cell Biol. 24:632–641.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wotton D and Merrill JC: Pc2 and
SUMOylation. Biochem Soc Trans. 35:1401–1404. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
van Wijnen AJ, Bagheri L, Badreldin AA,
Larson AN, Dudakovic A, Thaler R, Paradise CR and Wu Z: Biological
functions of chromobox (CBX) proteins in stem cell self-renewal,
lineage-commitment, cancer and development. Bone. 143:1156592021.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou H, Xiong Y, Liu Z, Hou S and Zhou T:
Expression and prognostic significance of CBX2 in colorectal
cancer: Database mining for CBX family members in malignancies and
vitro analyses. Cancer Cell Int. 21:4022021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li J, Xu Y, Long XD, Wang W, Jiao HK, Mei
Z, Yin QQ, Ma LN, Zhou AW, Wang LS, et al: Cbx4 governs HIF-1α to
potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3
ligase activity. Cancer Cell. 25:118–131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang Z, Yan Y, Zhu Z, Liu J, He X,
Dalangood S, Li M, Tan M, Cai J, Tang P, et al: CBX7 suppresses
urinary bladder cancer progression via modulating AKR1B10-ERK
signaling. Cell Death Dis. 12:5372021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chandrashekar DS, Karthikeyan SK, Korla
PK, Patel H, Shovon AR, Athar M, Netto GJ, Qin ZS, Kumar S, Manne
U, et al: UALCAN: An update to the integrated cancer data analysis
platform. Neoplasia. 25:18–27. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Asplund A, Edqvist PHD, Schwenk JM and
Pontén F: Antibodies for profiling the human proteome-the human
protein atlas as a resource for cancer research. Proteomics.
12:2067–2077. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Survplot. URL. http://www.cbs.dtu.dk/~eklund/survplot2021 07 07
|
|
20
|
BeeSwarm. URL. http://www.cbs.dtu.dk/~eklund/beeswarm/2021 07 07
|
|
21
|
Therneau TM and Grambsch PM: Modeling
survival data: Extending the Cox model. New York, NY:
Springer-Verlag; 2000, View Article : Google Scholar
|
|
22
|
Wickham H: ggplot2. Elegant graphics for
data analysis. New York: Springer-Verlag; 2009
|
|
23
|
Wu W, Jia G, Chen L, Liu H and Xia S:
Analysis of the expression and prognostic value of annexin family
proteins in bladder cancer. Front Genet. 12:7316252021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lánczky A and Győrffy B: Web-based
survival analysis tool tailored for medical research (KMplot):
Development and implementation. J Med Internet Res. 23:e276332021.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45((W1)):
W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou Y, Zhou B, Pache L, Chang M,
Khodabakhshi AH, Tanaseichuk O, Benner C and Chanda SK: Metascape
provides a biologist-oriented resource for the analysis of
systems-level datasets. Nat Commun. 10:15232019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chatr-Aryamontri A, Oughtred R, Boucher L,
Rust J, Chang C, Kolas NK, O'Donnell L, Oster S, Theesfeld C,
Sellam A, et al: The BioGRID interaction database: 2017 Update.
Nucleic Acids Res. 45(D1): D369–D379. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bader GD and Hogue CWV: An automated
method for finding molecular complexes in large protein interaction
networks. BMC Bioinformatics. 4:22003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu
JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis
of tumor-infiltrating immune cells. Cancer Res. 77:e108–e110. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Thy S, Hommel A, Meneceur S, Bartkowiak
AL, Schulz WA, Niegisch G and Hoffmann MJ: Epigenetic treatment of
urothelial carcinoma cells sensitizes to cisplatin chemotherapy and
PARP inhibitor treatment. Cancers (Basel). 13:13762021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Harsanyi S, Novakova ZV, Bevizova K,
Danisovic L and Ziaran S: Biomarkers of bladder cancer: Cell-free
DNA, epigenetic modifications and non-coding RNAs. Int J Mol Sci.
23:132062022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
He M, Yue L, Wang H, Yu F, Yu M, Ni P,
Zhang K, Chen S, Duan G and Zhang R: Evaluation of the prognostic
value of CBXs in gastric cancer patients. Sci Rep. 11:123752021.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shiota M, Song Y, Yokomizo A, Tada Y,
Kuroiwa K, Eto M, Oda Y, Inokuchi J, Uchiumi T, Fujimoto N, et al:
Human heterochromatin protein 1 isoform HP1beta enhances androgen
receptor activity and is implicated in prostate cancer growth.
Endocr Relat Cancer. 17:455–467. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang YF, Pan YH, Tian QH, Wu DC and Su SG:
CBX1 indicates poor outcomes and exerts oncogenic activity in
hepatocellular carcinoma. Transl Oncol. 11:1110–1118. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hu K, Yao L, Xu Z, Yan Y and Li J:
Prognostic value and therapeutic potential of CBX family members in
ovarian cancer. Front Cell Dev Biol. 10:8323542022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hu A, Zhang Y, Zhao X, Li J and Ying Y:
CBX1 is a direct target of miR-205-5p and contributes to the
progression of pituitary tumor. Pharmazie. 74:154–156.
2019.PubMed/NCBI
|
|
39
|
Zhu Y, Pu Z, Li Z, Lin Y, Li N and Peng F:
Comprehensive analysis of the expression and prognosis value of
chromobox family members in clear cell renal cell carcinoma. Front
Oncol. 11:7005282021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Clermont PL, Sun L, Crea F, Thu KL, Zhang
A, Parolia A, Lam WL and Helgason CD: Genotranscriptomic
meta-analysis of the polycomb gene CBX2 in human cancers: Initial
evidence of an oncogenic role. Br J Cancer. 111:1663–1672. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hu FF, Chen H, Duan Y, Lan B, Liu CJ, Hu
H, Dong X, Zhang Q, Cheng YM, Liu M, et al: CBX2 and EZH2
cooperatively promote the growth and metastasis of lung
adenocarcinoma. Mol Ther Nucleic Acids. 27:670–684. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zheng S, Lv P, Su J, Miao K, Xu H and Li
M: Overexpression of CBX2 in breast cancer promotes tumor
progression through the PI3K/AKT signaling pathway. Am J Transl
Res. 11:1668–1682. 2019.PubMed/NCBI
|
|
43
|
Huo W, Tan D and Chen Q: CASC9 facilitates
cell proliferation in bladder cancer by regulating CBX2 expression.
Nephron. 144:388–399. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen LY, Cheng CS, Qu C, Wang P, Chen H,
Meng ZQ and Chen Z: Overexpression of CBX3 in pancreatic
adenocarcinoma promotes cell cycle transition-associated tumor
progression. Int J Mol Sci. 19:17682018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lin H, Lian J, Xia L, Guan G and You J:
CBX3 promotes gastric cancer progression and affects factors
related to immunotherapeutic responses. Cancer Manag Res.
12:10113–10125. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Alam H, Li N, Dhar SS, Wu SJ, Lv J, Chen
K, Flores ER, Baseler L and Lee MG: HP1γ promotes lung
adenocarcinoma by downregulating the transcription-repressive
regulators NCOR2 and ZBTB7A. Cancer Res. 78:3834–3848. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jin X, Zhang B, Zhang H and Yu H:
Smoking-associated upregulation of CBX3 suppresses ARHGAP24
expression to activate Rac1 signaling and promote tumor progression
in lung adenocarcinoma. Oncogene. 41:538–549. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Huang Y, Lin Y, Song X and Wu D: LINC00857
contributes to proliferation and lymphomagenesis by regulating
miR-370-3p/CBX3 axis in diffuse large B-cell lymphoma.
Carcinogenesis. 42:733–741. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cai H, Yu Y, Ni X, Li C, Hu Y, Wang J,
Chen F, Xi S and Chen Z: LncRNA LINC00998 inhibits the malignant
glioma phenotype via the CBX3-mediated c-Met/Akt/mTOR axis. Cell
Death Dis. 11:10322020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang X, Qin G, Liang X, Wang W, Wang Z,
Liao D, Zhong L, Zhang R, Zeng YX, Wu Y and Kang T: Targeting the
CK1α/CBX4 axis for metastasis in osteosarcoma. Nat Commun.
11:11412020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hu C, Zhang Q, Tang Q, Zhou H, Liu W,
Huang J, Liu Y, Wang Q, Zhang J, Zhou M, et al: CBX4 promotes the
proliferation and metastasis via regulating BMI-1 in lung cancer. J
Cell Mol Med. 24:618–631. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zeng JS, Zhang ZD, Pei L, Bai ZZ, Yang Y,
Yang H and Tian QH: CBX4 exhibits oncogenic activities in breast
cancer via Notch1 signaling. Int J Biochem Cell Biol. 95:1–8. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang X, Li L, Wu Y, Zhang R, Zhang M, Liao
D, Wang G, Qin G, Xu RH and Kang T: CBX4 suppresses metastasis via
recruitment of HDAC3 to the Runx2 promoter in colorectal carcinoma.
Cancer Res. 76:7277–7289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wu C and Zhang J: Long non-conding RNA
LOXL1-AS1 sponges miR-589-5p to up-regulate CBX5 expression in
renal cell carcinoma. Biosci Rep. 40:BSR202002122020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sun Y, Wang X and Bu X: LINC02381
contributes to cell proliferation and hinders cell apoptosis in
glioma by transcriptionally enhancing CBX5. Brain Res Bull.
176:121–129. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zheng H, Jiang WH, Tian T, Tan HS, Chen Y,
Qiao GL, Han J, Huang SY, Yang Y, Li S, et al: CBX6 overexpression
contributes to tumor progression and is predictive of a poor
prognosis in hepatocellular carcinoma. Oncotarget. 8:18872–18884.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Deng H, Guan X, Gong L, Zeng J, Zhang H,
Chen MY and Li G: CBX6 is negatively regulated by EZH2 and plays a
potential tumor suppressor role in breast cancer. Sci Rep.
9:1972019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Sakai K, Nishiuchi T, Tange S, Suzuki Y,
Yano S, Terashima M, Suzuki T and Matsumoto K: Proteasomal
degradation of polycomb-group protein CBX6 confers MMP-2 expression
essential for mesothelioma invasion. Sci Rep. 10:166782020.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Pallante P, Forzati F, Federico A, Arra C
and Fusco A: Polycomb protein family member CBX7 plays a critical
role in cancer progression. Am J Cancer Res. 5:1594–1601.
2015.PubMed/NCBI
|
|
60
|
Li J, Ouyang T, Li M, Hong T, Alriashy M,
Meng W and Zhang N: CBX7 is dualistic in cancer progression based
on its function and molecular interactions. Front Genet.
12:7407942021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Huang Z, Liu J, Yang J, Yan Y, Yang C, He
X, Huang R, Tan M, Wu D, Yan J and Shen B: PDE4B induces
epithelial-to-mesenchymal transition in bladder cancer cells and is
transcriptionally suppressed by CBX7. Front Cell Dev Biol.
9:7830502021. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Li R, Yan Q, Tian P, Wang Y, Wang J, Tao
N, Ning L, Lin X, Ding L, Liu J and Ma C: CBX7 inhibits cell growth
and motility and induces apoptosis in cervical cancer cells. Mol
Ther Oncolytics. 15:108–116. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Pallante P, Terracciano L, Carafa V,
Schneider S, Zlobec I, Lugli A, Bianco M, Ferraro A, Sacchetti S,
Troncone G, et al: The loss of the CBX7 gene expression represents
an adverse prognostic marker for survival of colon carcinoma
patients. Eur J Cancer. 46:2304–2313. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Gong L, Tang Y, Jiang L, Tang W and Luo S:
Regulation of circGOLPH3 and its binding protein CBX7 on the
proliferation and apoptosis of prostate cancer cells. Biosci Rep.
40:BSR202009362020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Shinjo K, Yamashita Y, Yamamoto E,
Akatsuka S, Uno N, Kamiya A, Niimi K, Sakaguchi Y, Nagasaka T,
Takahashi T, et al: Expression of chromobox homolog 7 (CBX7) is
associated with poor prognosis in ovarian clear cell adenocarcinoma
via TRAIL-induced apoptotic pathway regulation. Int J Cancer.
135:308–318. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhang CZ, Chen SL, Wang CH, He YF, Yang X,
Xie D and Yun JP: CBX8 exhibits oncogenic activity via
AKT/β-catenin activation in hepatocellular carcinoma. Cancer Res.
78:51–63. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zeng F, Luo L, Li D, Guo J and Guo M:
KPNA2 interaction with CBX8 contributes to the development and
progression of bladder cancer by mediating the PRDM1/c-FOS pathway.
J Transl Med. 19:1122021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Baci D, Bosi A, Gallazzi M, Rizzi M,
Noonan DM, Poggi A, Bruno A and Mortara L: The Ovarian cancer tumor
immune microenvironment (TIME) as target for therapy: A focus on
innate immunity cells as therapeutic effectors. Int J Mol Sci.
21:31252020. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Rohaan MW, van den Berg JH, Kvistborg P
and Haanen JBAG: Adoptive transfer of tumor-infiltrating
lymphocytes in melanoma: A viable treatment option. J Immunother
Cancer. 6:1022018. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Okła K, Farber DL and Zou W:
Tissue-resident memory T cells in tumor immunity and immunotherapy.
J Exp Med. 218:e202016052021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Li B, Severson E, Pignon JC, Zhao H, Li T,
Novak J, Jiang P, Shen H, Aster JC, Rodig S, et al: Comprehensive
analyses of tumor immunity: Implications for cancer immunotherapy.
Genome Biol. 17:1742016. View Article : Google Scholar : PubMed/NCBI
|
